---
schema_version: "secwatch.filing_event.v1"
accession: "0001534120-26-000026"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2026-04-28T23:59:59+00:00"
generated_at: "2026-05-15T02:50:49.805535+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Avalo Therapeutics buys option to reduce AlmataBio milestone from $15M to $7.375M

## Summary
- Pays $2.25M upfront for 90-day option to pay $5.125M (cash/stock) in lieu of $15M Phase 3 dosing milestone.
- If option not exercised, $12.75M milestone remains due upon first patient in Phase 3 trial.
- Agreement amends March 2024 Merger Agreement for AlmataBio acquisition.
- Effective April 26, 2026; option decision due within 90 days.

## SEC filing metadata
- accession: 0001534120-26-000026
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2026-04-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000153412026000026/0001534120-26-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000153412026000026/avtx-20260426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001534120-26-000026
- JSON: https://secwatch.observer/filing/0001534120-26-000026.json
- Plain text: https://secwatch.observer/filing/0001534120-26-000026.txt

## Source-grounded claims
- claim_id: 50b0c28eae37f5e41b240285322bc9bec7aee4e1
  claim: Avalo Therapeutics, Inc. amended Milestone Buyout Option Agreement and Amendment to Agreement and Plan of Merger and Reorganization with AlmataBio, Inc. and Patrick J. Crutcher, solely as representative agent and attorney-in-fact of the former holders of securities in AlmataBio valued at $2.25 million (effective 2026-04-26).
  evidence_excerpt: On April 26, 2026 (the “ Effective Date ”), Avalo Therapeutics, Inc. (the “ Company ”) entered into a Milestone Buyout Option Agreement and Amendment to Agreement and Plan of Merger and Reorganization (the “ Milestone Buyout and Amendment Agreement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000153412026000026/0001534120-26-000026-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.